President Donald Trump’s latest effort to reshape the U.S. childhood vaccination schedule could require major changes to how vaccines are manufactured, administered and delivered to families.
An executive order signed Monday directs federal health officials to develop plans for separating combination vaccines and allowing greater spacing between routine childhood immunizations. The proposal has drawn strong criticism from public health specialists, who say there is no established medical benefit to routinely breaking apart combination vaccines.
The White House says the initiative is intended to give parents and doctors more flexibility over the timing and sequence of childhood vaccinations.
MMR vaccine at the center of the debate
The measles, mumps and rubella vaccine, commonly known as MMR, is one of the most prominent examples affected by the proposal.
The three diseases are currently covered by a combined vaccine in the United States. Separating them would require individual measles, mumps and rubella vaccines to be developed, tested, manufactured and approved for widespread use.
That would represent a major change from the system that has been standard in the U.S. for decades.
The executive order calls for federal officials to develop recommendations within 90 days on separating the MMR vaccine and potentially spacing out other childhood immunizations.
Drugmakers could face years of work
Turning the proposal into reality would not happen simply by changing federal guidance. Pharmaceutical manufacturers would need to produce individual vaccines and satisfy federal safety, manufacturing and licensing requirements.
Former federal vaccine regulators and pharmaceutical experts have said companies could need new clinical studies and manufacturing facilities before separate vaccines could be introduced.
Manufacturing facilities for vaccines can take years to design, construct and obtain regulatory approval. Individual products would also need their own regulatory reviews.
There is currently little commercial incentive for manufacturers to make separate versions of vaccines already available in combination form. Producing multiple individual products could increase costs while creating competition with vaccines companies already sell.
Parents could face more medical appointments
The proposed approach could also substantially increase the number of visits families make to pediatricians.
The MMR vaccine is generally administered in two doses during childhood. If measles, mumps and rubella vaccinations were routinely separated, children could require six injections administered at different appointments instead of two combination-vaccine visits.
Spacing out other vaccinations could add even more appointments.
Public health specialists warn that additional visits could create practical barriers for families, particularly those who have difficulty taking time away from work, arranging transportation or accessing pediatric care.
Dr. Anna Durbin of Johns Hopkins Bloomberg School of Public Health said making vaccination less convenient could ultimately result in fewer children being fully immunized.
Scientific evidence does not support an autism link
Trump has repeatedly questioned the number and timing of vaccines given to American children, while federal health officials under his administration have revisited longstanding vaccination policies.
However, extensive research has found no credible evidence that the MMR vaccine causes autism.
Studies involving large populations have found no increased autism risk associated with MMR vaccination, including research involving children considered at higher risk of autism. The original 1998 paper that helped popularize the vaccine-autism claim was later retracted.
Federal vaccine materials have also documented the absence of convincing evidence connecting vaccines with autism.
Executive order does not force manufacturers to act
The presidential order cannot by itself require pharmaceutical companies to create new vaccines.
The Food and Drug Administration and other federal agencies can regulate and approve vaccines, but manufacturers ultimately decide which products to develop and pursue through the approval process.
That means the administration’s proposal could face significant practical and commercial obstacles even if federal agencies produce recommendations supporting separate shots.
The order also does not directly give the federal government authority to impose new school vaccination requirements. Vaccination mandates for school attendance are generally established by individual states.
Debate could reshape U.S. vaccine policy
The administration has argued that the United States should bring its childhood immunization practices closer to those of other developed countries and provide families with greater flexibility.
Public health experts, meanwhile, warn that delaying or separating vaccines without a medical reason could make it harder for children to receive timely protection against preventable diseases.
The proposal therefore faces two separate questions: whether federal officials can change recommendations and whether manufacturers, doctors and parents will actually adopt the resulting system.
For families, the most immediate potential change would be straightforward but significant — more injections, more appointments and potentially higher costs to achieve the same protection against childhood diseases.